Guía de Práctica Clínica Trastornos Hipertensivos del Embarazo.
40. Churchill D, Duley L. Interventionist versus expectant care for severe pre-eclampsia before term. Cochrane Database Syst Rev. 2002; (3): CD003106. 41. Haddad B, Sibai BM. Expectant management in pregnancies with severe pre-eclampsia. Semin Perinatol. 2009 Jun; 33 (3): 143-51. 42. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003 Oct 25; 327 (7421): 955-60. 43. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007 Jan 24; (1): CD002252. 44. Atallah AN, Torloni MR. Anticonvulsant therapy for eclampsia: RHL commentary (last revised: 1 November 2011). The WHO Reproductive Health Library; Geneva: World Health Organization. 45. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002 Jun 1;359(9321):1877-90. 46. Magpie Trial Follow-Up Study Collaborative Group. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years. BJOG. 2007 Mar; 114 (3): 300-9. 47. Atkinson MW, Belfort MA, Saade GR, Moise KJ Jr. The relation between magnesium sulfate therapy and fetal heart rate variability. Obstet Gynecol. 1994 Jun; 83 (6): 967-70. 48. MSP Proyecto MODERSA. Manual para la referencia y contrarreferencia de pacientes y usuarios. Quito: MSP; 2004 abril. 49. Ministerio de Salud Pública del Ecuador. Manual de estándares, indicadores e instrumentos para medir la calidad de la atención materno neonatal. Quito: MSP; 2008.
36